Stock Research: Eli Lilly

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Eli Lilly

NYQ:LLY US5324571083
92
  • Value
    46
  • Growth
    72
  • Safety
    Safety
    84
  • Combined
    84
  • Sentiment
    91
  • 360° View
    360° View
    92
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Eli Lilly and Company is a medicine company that discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. It operates in the pharmaceutical industry, with products including Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity, and Zepbound, among others. The company operates globally. In the last fiscal year, the company had a market cap of $731,415 million, profits of $36,624 million, and revenue of $45,043 million with 47,000 employees.

more

ANALYSIS: With an Obermatt 360° View of 92 (better than 92% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Eli Lilly are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Eli Lilly. The consolidated Growth Rank has a good rank of 72, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 72% of competitors in the same industry. The consolidated Safety Rank at 84 means that the company has a financing structure that is safer than 84% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 91, which means that professional investors are more optimistic about the stock than for 91% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 46, meaning that the share price of Eli Lilly is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 54% of alternative stocks in the same industry. ...read more

more
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 20 12 27
Growth
72 89 77 19
Safety
Safety
84 39 28 20
Sentiment
91 76 81 34
360° View
360° View
92 55 40 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
25 79 52 31
Opinions Change
50 62 52 48
Pro Holdings
n/a 48 91 45
Market Pulse
100 67 67 62
Sentiment
91 76 81 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 20 12 27
Growth
72 89 77 19
Safety Safety
84 39 28 20
Combined
84 43 22 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
42 5 3 16
Price vs. Earnings (P/E)
8 24 9 24
Price vs. Book (P/B)
5 1 1 4
Dividend Yield
99 84 85 86
Value
46 20 12 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
74 67 82 11
Profit Growth
100 90 29 36
Capital Growth
19 54 55 34
Stock Returns
49 69 87 87
Growth
72 89 77 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
13 18 19 13
Refinancing
88 14 17 7
Liquidity
100 61 89 93
Safety Safety
84 39 28 20

Similar Stocks

Discover high‑ranked alternatives to Eli Lilly and broaden your portfolio horizons.

D.R. Horton

NYQ:DHI
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: